Late Breaking Clinical Trials 1

8 Feb 2025 5:30 p.m. 6:30 p.m.

Jasmine Das Moderator

Time	Session

12 a.m. 12 a.m.	ECONOMIC IMPACT DUE TO SARS-COV2 INFECTION IN VACCINATED AND UNVACCINATED KIDNEY TRANSPLANT PATIENTS DURING 2021 WCN25-AB-1258, Poster Board= SAT-465	EARLY VERSUS CONVENTIONAL INITIATION OF RENAL REPLACEMENT THERAPY IN CHILDREN WITH ACUTE KIDNEY INJURY: A RANDOMIZED CONTROLLED TRIAL WCN25-AB-981, Poster Board= SAT-466	BONE MINERAL DENSITY PROFILE IN CHILDREN RECEIVING CORTICOSTEROIDS FOR RENAL INDICATIONS FOR MORE THAN TWELVE WEEKS WCN25-AB-2795, Poster Board= SAT-467	TO DETERMINE THE CLINICAL OUTCOMES IN DECEASED DONOR/LIVE RENAL TRANSPLANT RECIPIENTS WHO WERE CHANGED FROM MYCOPHENOLATE MOFETIL(MMF) TO AZATHIOPRINE(AZA) BASED TRIPLE IMMUNOSUPPRESSION. WCN25-AB-4244, Poster Board= SAT-468	DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE WCN25-AB-888, Poster Board= SAT-469	A PHASE 1/2 TRIAL OF ZIGAKIBART IN IGA NEPHROPATHY (IGAN) WCN25-AB-1585, Poster Board= SAT-470	DESIGN OF RANDOMIZED EMBEDDED ADAPTIVE PLATFORM CLINICAL TRIAL IN SOUTH ASIAN KIDNEY BIOPSY-PROVEN PRIMARY GLOMERULAR DISEASES: MULTI-CENTER, MULTI-ARM AND MULTI-STAGE WCN25-AB-3803, Poster Board= SAT-471